Connect with us

Cannabis News

Pharmaceutical Companies Win Big with Schedule 3 Classification of Cannabis

Published

on


big pharma schedule 3

Pharma wins in Schedule III – De-scheduling is the only way for true Equity!

The Biden Administration has been loudly touting diversity, equity and inclusion as top priorities since taking office, particularly when it comes to cannabis policy reform. However, their recent proposal to reschedule cannabis from a Schedule I to a Schedule III controlled substance reveals that promoting true equity is far from their primary concern.

For decades, Joe Biden has been cozy with Big Pharma, accepting millions in campaign contributions from drug companies over his long political career. It’s no secret that the pharmaceutical industry vehemently opposes cannabis legalization, as legal weed represents a major threat to their profits from opiate painkillers and other drugs. Pharma much prefers that cannabis remain illegal, or barring that, placed into a restrictive category like Schedule III that they can control and corner the market on.

Rescheduling cannabis to Schedule III would allow the drug to be legally prescribed, but with strict controls and oversight from the FDA. This plays right into the hands of major drug companies, who have the resources to navigate the complicated federal approval process and bring cannabis-derived pharmaceuticals to market. Smaller entrepreneurs, especially minorities who have been disproportionately impacted by the War on Drugs, would be largely shut out from participating in the industry.

If the Biden administration truly cared about diversity, equity and inclusion in cannabis, they would push to completely deschedule the plant, rather than shifting it to Schedule III. Descheduling would open up opportunities for a much wider range of individuals and small businesses to enter the legal industry. It would begin to repair the harms of the drug war and create more equitable access.

But Biden has never been a real ally to cannabis reform or racial justice. His proposed rescheduling is a pharma market grab disguised as incremental progress. Allowing a corporate oligopoly to further enrich itself will do nothing to help the marginalized communities who have suffered the most under prohibition. Only full descheduling can pave the way for true equity in the cannabis space. The administration’s “diversity and inclusion” rhetoric around this issue rings completely hollow.

Rescheduling cannabis to Schedule III would place it under the strict purview of the FDA, subjecting the industry to onerous regulations and compliance burdens that disadvantage minority small business owners. The costs of operating a Schedule III business are prohibitively high for most entrepreneurs. Companies must navigate an arduous FDA approval process for each cannabis-derived product, which can take years and cost millions of dollars in research and legal fees.

According to a 2017 survey, only 4% of cannabis businesses are owned by African Americans, and less than 2% by Latinos. These numbers are unlikely to improve under a Schedule III system that favors deep-pocketed corporations. Existing minority-owned cannabis businesses, already facing capital access challenges, would struggle immensely to shoulder the regulatory costs of FDA compliance, likely driving many out of business entirely.

Businesses would have to implement robust quality control systems, conduct expensive clinical trials, and maintain meticulous production records to meet FDA standards. The agency’s Good Manufacturing Practices are notoriously difficult to comply with, requiring significant investments in specialized facilities and equipment. Companies would also face extensive labeling and marketing restrictions, with the FDA tightly controlling allowable claims and product information.

While Schedule III substances can be legally prescribed and sold, they are still considered illegal outside of FDA-approved channels. Cannabis would remain a federally illegal substance, with businesses still facing the threat of raids and asset forfeiture. This “Regulatory Prohibition” would likely be weaponized against minority operators, as the drug war has been for decades. Those without the means to fight regulators could find themselves criminalized under the new system.

The pharmaceutical industry, through lobbying and campaign contributions, would inevitably seek to shape the FDA’s cannabis regulations in their favor. This could lead to policies like dosage limits and bans on whole-plant products that benefit patented drugs while hindering small producers. Pharma’s influence would further tilt the playing field against minority owners.

For minority entrepreneurs, the costs of entry and compliance under Schedule III would be backbreaking. Without serious equity initiatives to provide resources and technical assistance, a Schedule III industry would be dominated by Big Pharma and exclude people of color, doing little to repair the injustices of the drug war.

As we debate the future of cannabis policy in America, we must first ask ourselves: why are we even considering legalization in the first place? The answer is clear – it is the will of the people. For over a decade, a steadily growing majority of U.S. citizens have believed that cannabis should be legal. A recent poll found that a staggering 91% of Americans support legalizing medical marijuana, and 7 out of 10 are in favor of recreational legalization as well. The public has spoken, and they have resoundingly rejected the failed policies of prohibition.

So why, then, are we wasting time debating incremental “rescheduling” measures like moving cannabis to Schedule III? The only rational discussion to be having at this point is how to deschedule marijuana entirely and implement full legalization nationwide. Anything less is a slap in the face to the supermajority of Americans who want the freedom to consume cannabis without fear of arrest or stigma.

Activists like RAW Josh on X (formerly Twitter) are absolutely right to be outraged at the suggestion of Schedule III as some kind of victory.

It is not a win for the cannabis community, who have fought for decades to end prohibition entirely. It is not a win for those who have had their lives ruined by the cruel excesses of the Drug War, disproportionately people of color. It is not a win for medical patients, who would still face significant federal restrictions on their medicine. And it is certainly not a win for entrepreneurs and small businesses, who would be steamrolled by the pharmaceutical industry under a Schedule III paradigm.

What Schedule III represents is the iron grip of corporate pharma influence on our political system. It is a calculated maneuver to co-opt the legalization movement and steer the industry into the waiting hands of a few powerful drug companies. Roughly half of the funding of the FDA comes from Pharmaceutical companies through a scheme called “User Fees”.  Since Pharma loses roughly $10 billion annually in a region where Medical Cannabis is legal…what do you think happens to these “fees” that the FDA receive.

By maintaining strict federal control over cannabis, the government can pick and choose winners in the market, and rest assured those winners will not be mom-and-pop pot shops or minority-owned startups. They will be the multinational corporations with the lobbying power to write the regulations in their favor.

We cannot allow this to happen. We cannot allow the will of the people to be subverted by special interests yet again. The cannabis community must stand firm and demand nothing less than full descheduling and an end to federal prohibition once and for all. We must reject half-measures like Schedule III that are designed to fail us while enriching a corrupt pharmaceutical industry.

If that means we have to completely overhaul the DEA, or dismantle the incentive structures that allow corporations to buy off politicians, so be it. The war on drugs has been one of the most destructive and wasteful policy failures in American history, and it will not end until we take bold, uncompromising action. The people are ready for change, and we will continue to fight for it, against all odds and all opposition, until our work is finished. Descheduling is the path to justice, to equity, to individual liberty. We cannot settle for anything less.

When it comes to cannabis policy, the sticky bottom line is this: Schedule III is not what activists and advocates have been fighting for all these years. It is a far cry from the full legalization and normalization we seek. As citizens, it is imperative that we make our voices heard on this issue, not just in who we elect as president, but perhaps more importantly, in who we choose to represent us in Congress.

The unfortunate reality is that many of our current elected officials are political dinosaurs, beholden to special interests like Big Pharma who line their campaign coffers with cash. They are out of touch with the will of the people and more concerned with serving their corporate masters than doing what’s right. It is time we vote these compromised individuals out of office and replace them with representatives who will stand up to the pharmaceutical lobby and fight for true cannabis freedom.

What we demand is nothing less than complete descheduling of this miraculous plant. Because that’s what cannabis is at the end of the day – a plant. It is a seed that we can sow into the earth, a gift from nature that grows abundantly without human intervention. For centuries, humans have cultivated cannabis for food, fiber, medicine and spiritual purposes. Who are we to criminalize a plant that has served us so well?

The right to grow our own sustenance and healing herbs is fundamental to our autonomy as free people. Without that right, can we truly call ourselves free? Or are we merely slaves, dependent on the permission of corporations and governments to access the necessities of life? That is the question each of us must ask ourselves as we contemplate the future of cannabis in America.

In the end, the sticky bottom line is a matter of principle. Will we stand up for what we believe in, even in the face of powerful opposition? Will we fight for our sovereignty and self-determination, no matter how long it takes? Or will we compromise our values for the sake of political expediency and allow ourselves to be subjugated by those who seek to control us? The choice is ours to make, and the consequences will be ours to bear. Let us choose wisely, and let us never give up until the battle is won.

 

MORE ON SCHEDULE 3, READ ON…

WINNERS AND LOSERS FROM SCHEDULE 3

THE WINNERS AND LOSERS FROM SCHEDULE 3 CANNABIS!



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis News

The 3 Biggest Winners from Rescheduling Cannabis?

Published

on

By


tax money weed

President Joe Biden’s support of the administration’s decision to reschedule cannabis from Schedule I to Schedule III is likely to result in considerable financial benefits for large, legal cannabis businesses and the illicit market. This action may lessen the restrictions imposed by IRS tax regulation 280E, which has banned cannabis businesses from deducting standard business expenditures. Which cannabis firms will gain the most from this change?

 

The illicit market will get a huge boost by removing the punshiments associated with getting caught dealing or transporting a Schedule 1 drug.  Now that the fines, prison sentences, and desire to enforce Schedule 3 crimes is lessened, look for the illicit market to boom across America.  It is estimated that the illegal cannabis market is 3x the size of the legal US market as of 2024, so look for that multiple to expand if Schedule 3 is enacted.  Removing a negative incentive in economics always leads to predictable action.

 

In the legal market, the largest MSOS, or those that paid the most taxes, have the most to gain by a repeal of the 280E tax code and future tax credit or refunds coming their way

 

Industry Leaders in Tax Payments

 

Rescheduling cannabis will abolish the onerous 280E tax law, potentially freeing up more than a billion dollars in tax savings for the business. Curaleaf (OTC: CURLF) and Trulieve (OTC: TCNNF), both of which make considerable tax payments, are among the firms most likely to profit. Repealing 280E limits would allow these businesses to deduct typical business costs, greatly improving their financial situation.

Truelive alone stands to get $113,000,000 in tax refunds and savings!

Senior analyst Pablo Zuanic of Zuanic & Associates believes that these tax reductions may result in improved cash flows, allowing these businesses to reinvest in development and growth. In the quickly changing cannabis market, having this kind of financial flexibility is essential for keeping a competitive advantage and encouraging creativity.

 

Zuanic has consistently highlighted the disparity between current market valuations and the potential upside, particularly if federal legalization occurs. He emphasizes that immediate cash flow improvements could lead to substantial revaluation of these companies. By enabling the deduction of ordinary business expenses, the financial statements of these companies would more accurately reflect their true profitability, attracting more investors and boosting market confidence.

 

The potential tax savings are a temporary relief and a game-changer for the industry. Analysts believe that the improved cash flow could result in substantial revaluations of cannabis companies. For Curaleaf and Trulieve, this change would mean their financial statements would better represent their actual profitability, leading to increased investments and further expansion opportunities.

 

Curaleaf’s Financial Outlook

 

Beacon Securities’ Russell Stanley sheds light on Curaleaf’s financial landscape, highlighting the company’s adept management of operating cash flow. This proficiency facilitated a successful debt repurchase post-quarter, significantly enhancing its financial stability. With the anticipated rescheduling of cannabis and the potential enactment of the SAFER Banking Act, Curaleaf stands to benefit from a transformed financial environment, potentially witnessing a substantial surge in its operating cash flow by up to 92% and free cash flow by 188%.

 

Wedbush Securities recently released a report on Curaleaf, elevating the stock’s 12-month price target from $6.00 to $7.00 while maintaining a buy recommendation. The report underscores Curaleaf’s commendable performance in key domestic markets like Connecticut, Arizona, Maryland, and New York. Projections indicate a revenue uptick to $1.50 billion by 2025, coupled with improvements in overall profitability. This optimistic forecast reflects the company’s robust financial position and its strategic market presence.

 

Proactive debt management techniques and well-thought-out market positioning highlight Curaleaf’s potential for long-term development and financial success in the changing cannabis industry. Curaleaf is in a strong position to benefit from the rescheduling of banking and cannabis legislation, which may lower regulatory obstacles and further establish the company’s leadership in the cannabis market.

 

Unlocking Trulieve’s Growth Potential

 

Trulieve’s Growth Trajectory

 

Trulieve’s growth trajectory is drawing attention, particularly from Needham’s Matt McGinley, who emphasizes the company’s operational efficiency. McGinley points out that Trulieve has achieved its highest gross margin and EBITDA rates observed in over two years, indicating strong operational performance. This efficiency positions Trulieve favorably for capitalizing on emerging opportunities in the cannabis market.

 

Key legislative advancements in pivotal markets such as Florida and Pennsylvania present significant growth potential for Trulieve. As these markets potentially transition to adult-use cannabis, Trulieve stands to benefit from increased demand and expanded market reach. Leveraging its operational efficiency and established market presence, Trulieve is poised to capitalize on these legislative shifts to drive revenue growth and enhance shareholder value.

 

Trulieve is positioned to be a major participant in the growth of the cannabis sector due to its strategic focus on operational excellence and its flexibility in responding to changing regulatory environments. Trulieve is in an excellent position to maintain its growth trajectory and establish itself as a top cannabis supplier, thanks to encouraging legislative changes and a proven track record of high performance.

 

Analysts’ Industry Impact Assessment

 

Viridian Capital Advisors offers insights into the industry impact, noting that ten MSOs exceeded EBITDA estimates by $37 million in the first quarter of 2024. This performance suggests that initial projections may have been conservative, indicating a positive trend for cannabis companies. Analysts from Viridian specifically highlight Curaleaf and Trulieve, among others, as poised to benefit from the financial changes resulting from the removal of 280E tax restrictions.

 

The long-term outlook for the cannabis industry remains bullish, with potential federal legalization driving substantial valuation growth. Pablo Zuanic from Zuanic & Associates suggests that the US market alone could justify over $110 billion in valuations by 2030 assuming federal legalization. The removal of tax restrictions would directly impact bottom lines, potentially leading to significant valuation increases for many cannabis stocks.

 

All things considered, the possible repeal of the 280E tax laws offers cannabis businesses a big chance to improve their financial standing and market value. As analysts speculate that early projections may have overestimated the sector’s potential, businesses like Curaleaf and Trulieve might gain from more cash flow and better profitability, setting them up for long-term success in the changing cannabis market environment.

 

Bottom Line

 

The impending rescheduling of cannabis and the potential repeal of IRS tax regulation 280E offer a substantial opportunity for cannabis companies to strengthen their financial positions and market appeal. Industry leaders such as Curaleaf and Trulieve stand to benefit significantly, with projected increases in cash flow and profitability paving the way for sustained growth. Analysts anticipate a positive market response, with potential valuation growth and a bullish outlook for the long-term trajectory of the cannabis industry. These regulatory changes mark a pivotal moment, allowing businesses to capitalize on newfound financial flexibility and attract investor confidence. As the sector continues to evolve, Curaleaf, Trulieve, and other key players are positioned to thrive, driving innovation and shaping the future of the cannabis market.

 

WINNERS AND LOSERS FROM SCHEDULE 3, READ ON…

WINNERS FROM SCHEDULE 3 MARIJUANA

WINNERS AND LOSERS FROM SCHEDULE 3 CANNABIS, BET ON THIS!



Source link

Continue Reading

Cannabis News

How Potent is Illegal Weed

Published

on

By


potency of street weed

The average THC potency of illegal weed is only 16%, same as legal cannabis says DEA?

In the ever-changing landscape of cannabis, a striking revelation has come from the U.S. Drug Enforcement Administration (DEA). A recent statement established that the average potency of illicit marijuana flower stands at a industry standard of 16%. Understanding the implications of such a percentage requires a deeper dive into the realm of cannabinoids, particularly THC (tetrahydrocannabinol).

 

 The Evolution of THC Potency

THC is the main psychoactive compound in marijuana, responsible for the “high” that users experience. The potency of marijuana, measured by its THC content, has dramatically increased over the past few decades. To understand the context:

 

  • 1980s:The average THC content of seized marijuana was below 4%.

  • 1990s: This figure began to climb, reaching around 5-6%.

  • 2000s: Potency continued to increase, hitting approximately 10-12%.

  • 2020s: Current reports indicate an average of 16%, with some samples even exceeding 30%.

 

This increase is primarily due to advanced cultivation techniques, genetic selection, and the growing demand for stronger marijuana.

 

Factors Contributing to Increased THC Potency

Several factors have contributed to the rising THC levels in illicit marijuana:

 

  • Selective Breeding: Growers have increasingly focused on breeding strains with higher THC content to meet market demand.

  • Advanced Cultivation Techniques: Techniques such as hydroponics, controlled environments, and optimized nutrient delivery have enabled the production of more potent marijuana.

  • Genetic Modification: Some strains have been genetically modified to enhance THC production.

 

Public Health Implications

 

The rise in THC potency has several significant public health implications:

  • Increased Risk of Negative Effects

  • Heightened Anxiety and Paranoia: Elevated THC levels can induce intense anxiety and paranoia, especially in inexperienced users or individuals with existing mental health issues.

  • Acute Psychosis: The likelihood of encountering psychotic episodes rises significantly with higher doses of THC.

  • Cognitive Decline: Prolonged use of marijuana with high THC content can result in enduring cognitive impairments, particularly impacting memory and learning abilities.

 

 

  • Adolescents: Young users are more susceptible to the negative effects of high-THC marijuana, including impacts on brain development.

  • Individuals with Mental Health Issues: Those with pre-existing mental health conditions may experience exacerbated symptoms.

 

  Regulatory and Law Enforcement Challenges

The DEA’s report underscores significant obstacles faced by law enforcement and regulatory agencies:

  • Persistent Black Market: Despite legalization in several states, the black market for marijuana persists, often offering more potent products than those available in legal dispensaries.

  • Ensuring Consumer Safety: The unregulated nature of black market products results in unpredictable potency and potential contamination with harmful substances.

 

To address these issues, regulatory bodies need to:

 

  • Implement Stricter Controls: Introduce more stringent regulations for marijuana potency in both legal and illegal markets.

  • Increase Monitoring and Enforcement: Enhance efforts to monitor and dismantle illegal growing operations.

  • Educating Consumers: Consumer education is crucial in mitigating the risks associated with high-THC marijuana

  • Public Awareness Campaigns: Launch campaigns to inform the public about the potential dangers of high-THC marijuana.

  • Educational Programs: Develop programs targeted at specific groups, such as adolescents, to educate them about the risks.

 

Key points to emphasize in these programs include:

 

  • Understanding THC Levels: Educate consumers on how to read and understand THC levels on product labels.

  • Recognizing Symptoms of Overconsumption: Teach users how to recognize signs of overconsumption and what to do if they experience adverse effects.

  • Safe Consumption Practices: Promote safe consumption practices, including starting with low doses and waiting to see the effects before consuming more.

 Future Trends and Research

Ongoing research and monitoring are essential to adapt to the evolving marijuana market:

  • Long-term Health Effects: Conduct studies to understand the long-term health effects of high-THC marijuana use.

  • Impact on Mental Health: Investigate the relationship between high-THC marijuana use and mental health conditions.

  • Comparative Studies: Compare the effects of high-THC marijuana with other forms, such as CBD-dominant strains, to provide a comprehensive understanding of marijuana’s impact.

Potential Solutions and Innovations

To address the challenges posed by high-THC marijuana, several solutions and innovations can be explored:

  • Development of Low-THC Strains: Encourage the development and use of low-THC, high-CBD strains that provide therapeutic benefits without strong psychoactive effects.

  • Improved Testing Methods: Invest in better testing methods to accurately measure THC content and detect contaminants.

  • Policy Reform: Advocate for policy reforms that support research and responsible use, including:

  • Incentives for Low-THC Products: Provide incentives for the production and sale of low-THC products.

  • Support for Medical Marijuana Research: Increase funding and support for research into the medical uses of marijuana.

Industrial and Economic Implications

The rise in THC potency also has significant industrial and economic implications:

 

The marijuana industry has become a significant economic driver in states where it is legal, contributing to tax revenues and job creation.

However, the black market remains a substantial challenge:

  • Revenue Losses: Illegal sales undermine tax revenues that could be used for public health and safety programs.

  • Market Competition: Legal businesses face unfair competition from black market operators who do not adhere to regulatory standards.

Engaging Stakeholders and Community

A critical aspect of addressing the challenges associated with high-THC marijuana is engaging with and gaining the support of local communities, policymakers, and industry leaders. The Ohio company has launched outreach programs to educate stakeholders about the benefits of bioplastics and the specific advantages of using hemp as a raw material.

Community involvement is crucial, especially in providing local farmers with the tools and knowledge needed to transition to hemp cultivation. Through:

 

  • Training Sessions

  • Pilot Programs

The company aims to build a robust local supply chain that can sustainably support large-scale bioplastic production.

 Conclusion

In conclusion, the DEA’s report on the average THC potency of illicit marijuana flower reaching 16% highlights the significant changes in the marijuana landscape over recent decades. This increase poses new challenges for public health, regulation, and consumer safety. Addressing these challenges requires a multi-faceted approach involving education, regulatory reforms, technological advancements, and community engagement. By fostering a comprehensive understanding of the risks and benefits associated with high-THC marijuana, stakeholders can work together to ensure that the benefits of marijuana legalization are maximized while minimizing potential harms. This approach promises a healthier, safer future for all users and communities involved.

 

IS WEED REALLY GETTING STRONGER, READ ON…

IS WEED GETTING STRONGER

IS MARIJUANA REALLY GETTING STRONGER AND MORE POTENT?



Source link

Continue Reading

Cannabis News

Is Your Kid Smoking or Vaping Weed?

Published

on

By


is my kid smoking weed

Marijuana for recreational and medicinal purposes is becoming more widely available and simpler to purchase every day. Furthermore, opinions about the drug’s possible risks have changed as a result of recent legislative modifications, especially among young teenagers.

 

While proper use of marijuana can offer health benefits for specific conditions, inappropriate use can lead to a variety of problems. It can severely impact health, situational judgment, memory, coordination, and more.

 

Given that marijuana has rapidly become a much more commonly used drug among young people, it is crucial to recognize the main signs of marijuana use in teens to ensure their safety and well-being.

 

Statistics on Child Marijuana Use

 

Though the stats may surprise you, marijuana is the most often used narcotic among teenagers. Among children between the ages of 12 and 17, the National Center for Drug Abuse reports that:

 

– Nearly 44% have tried marijuana in their lifetime, up from 37% in 2019.

– 35% used marijuana in the past year.

– Almost 7% of 12th graders use marijuana daily.

 

Regretfully, eighth, ninth, and tenth kids are exposed to an alarmingly high level of marijuana. Early usage is problematic since those who start using earlier have a greater likelihood of heavier use later in life.

 

How THC Impacts the Brain

 

The active element in cannabis is tetrahydrocannabinol (THC), which produces the “high” associated with marijuana. THC can be ingested by smoking cannabis flowers, vaping concentrated forms, or eating THC-infused foods. THC impacts the brain by interfering with processes that are typically controlled by naturally existing endocannabinoids.

 

The brain grows from birth to the mid-twenties, and consuming marijuana at a young age can interrupt this important development. Early marijuana usage appears to influence brain development, according to recent research.

 

The effects of cannabis on the brain are extensive:

 

– Executive Functioning: Skills necessary for daily life, such as focus, memory, problem-solving, planning, reasoning, and emotional control, are compromised.

– Working Memory: The ability to remember and later recall or use information is reduced.

– Lingering Effects: The impact of cannabis use can last well beyond the period of intoxication. Even if someone smokes on a weekend, the effects can persist into the following week. Regular use leads to a persistent decline in executive functioning, working memory, and other cognitive areas.

 

Cannabis use interferes with the brain’s circuits, and it remains uncertain whether the brain can fully recover if marijuana use is discontinued.

 

Signs Your Child is Using Cannabis

 

Recognizing if your child is using marijuana can involve noticing various signs, including:

 

– Hair or clothes with a pungent marijuana smell

– Red or bloodshot eyes

– Delayed reaction times

– Mood swings

– Laziness and tiredness

– Presence of marijuana-related paraphernalia

– Paranoia or anxiousness

– Increased hunger or “munchies”

 

Visible Signs of Marijuana Use

 

Shortly after usage, marijuana’s effects can be perceived both visually and aromatically. It is very suggestive of marijuana usage if your adolescent returns home with red or bloodshot eyes. Physical and mental delays in response times and problems with muscular coordination are further symptoms.

 

Cannabis has a unique fragrance that is another warning clue; it is frequently characterized as having a pungent, musky smell like that of a skunk. On your teen’s clothes, this odor might cling rather readily.

 

Changes in Emotional State

 

The body and mind might react differently to different strains or varieties of marijuana. Teenage marijuana usage is frequently indicated by mood swings, lethargy, and general exhaustion in their day-to-day demeanor. Depending on how their body responds, they might also seem nervous and exhibit an elevated heart rate.

 

Your youngster may struggle to focus at job, school, or home as a result of these changes, which frequently results in subpar performance and grades. This decrease might be a clear indication that marijuana use has turned into an addiction.

 

Educating Your Child about Marijuana

 

Regardless of whether you suspect your child is using cannabis, it’s important to discuss it. Parents and caregivers should talk about all types of dangerous substances, including nicotine, alcohol, and cannabis, with children as early as elementary school.

 

It’s important to be proactive and talk to your youngster about the risks associated with marijuana. These talks may serve to deter marijuana usage or at the very least postpone the initial experience until the mid-20s, when the brain is more completely matured.

 

As teenagers become older, their need for independence grows, which makes it harder for parents to control their actions. Still, parents need to persevere. It is significantly more dangerous to consume cannabis than it is uncomfortable to have a difficult talk.

 

Addressing Marijuana Use and Seeking Help

 

For teenagers’ wellbeing, it is essential to identify and treat marijuana usage. It’s crucial to handle the matter with compassion and support if you think your child may be consuming marijuana. Discussing its usage, the rationale behind it, and any possible hazards should come first in an honest and nonjudgmental discussion. Give your child access to a secure environment where they may talk about their thoughts and experiences. You can gain insight into their viewpoint and advice on how to make better decisions by having this discussion.

 

If using marijuana has become troublesome, you might think about getting professional assistance. Resources like therapists, counselors, and specialty treatment programs can provide your kid with the help they need. These specialists are qualified to deal with underlying problems including stress, peer pressure, or mental health disorders that may be causing drug use. Early intervention can stop the usage from getting worse and support your kid in creating healthy coping mechanisms. Getting a medical expert involved can also offer a methodical way to handle the matter and guarantee that your adolescent gets the treatment they need.

 

It is critical to be involved and supportive throughout the process. Encourage your kid to participate in activities that support their well-being and offer positive reinforcement for good habits. Stay educated about the services available in your area, and consider joining support groups for parents struggling with similar challenges. You can assist your child in navigating this difficult period and promote a healthy, drug-free future by keeping open communication and obtaining expert support as required.

 

Bottom Line

 

Parents need to be vigilant about the signs of marijuana use in their children, given its prevalence among teenagers and its potential impact on their health and development. Early detection, open communication, and seeking professional help if needed are key strategies for addressing marijuana use in adolescents. By providing support, education, and access to resources, parents can help guide their children towards healthier choices and a drug-free future.

 

HOW TO HAVE “THE TALK” WITH YOUR KIDS, READ ON..

TALKING TO YOUR KID ABOUT MARIJUANA TALK

TALKING TO YOUR KIDS ABOUT WEED, AGE APPRORIATE TIPS!



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media